Cavernous hemangioma of orbit

Summary

Cavernous hemangioma of orbit (MONDO:0001975) is a disease. A subtype of cavernous hemangioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cavernous hemangioma of orbit
Mondo ID	MONDO:0001975
DOID	DOID:14463
NCIT	C4546
SNOMED CT	254998002
UMLS	C0346352
MedGen	138059
GARD	0023049
Is cancer (heuristic)	no

Also known as: cavernous angioma of orbit · cavernous angioma of the orbit · cavernous hemangioma of the orbit · orbit cavernous angioma · orbit cavernous hemangioma

Disease family

This is a subtype of cavernous hemangioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › cavernous hemangioma › cavernous hemangioma of orbit

Related subtypes (6): intracranial cavernous angioma, dermal unilateral segmental cavernous angioma, giant hemangioma, cavernous hemangioma of colon, cavernous hemangioma of face, liver cavernous hemangioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.